Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives

• Tác giả: Charlotte Vermehren, Niels Westergaard
• Ngôn ngữ: eng
• ISBN-13: 978-3036551616
• ISBN-13: 978-3036551623
• ISBN: books978-3-0365-5161-6
• Thông tin xuất bản: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Mô tả vật lý: 1 electronic resource (224 p.)
• Bộ sưu tập: Tài liệu truy cập mở
• ID: 373928
• Chủ đề: 1. acute kidney injury; 2. early biomarker; 3. plasma neutrophil gelatinase-associated lipocalin; 4. Medicine; 5. Pharmaceutical industries

Tóm tắt

 Polypharmacy is a necessary and important aspect of drug treatment
  however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug-drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug-drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling
  the application of PGx-based guidance and/or decision tools for drug-gene and drug-drug gene interactions
  medication reviews
  development and application of deprescribing tools
  and drivers and barriers to overcome for successful implementation in the healthcare system.